Feed / CAI

Caris Life Sciences, Inc.

CAI

Healthcare · 26.26 +6.9% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Caris Life Sciences, Inc.'s move is being confirmed by its market group.

CAI accounts for 10.8% of the group's measured movement across 7.3 effective names. raw member direction is mixed; 6 of 10 SPY-adjusted paths align to the upside. Capital-flow agreement is 53%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#3 of 10 by movement share
Group movement share10.8%Absolute path energy—not portfolio weight
Relative path+2.68%aligned
Effective breadth7.3 / 10broad
Relative alignment6/10upside path · 4 counter-moving
Capital-flow agreement53%not yet clean
SEQUENCE READ

COGT, NTRA, VCYT moved materially before CAI. CAI crossed its material path threshold at 10:35 ET, 15 minutes after the first measured mover. MRNA, CRSP, SYRE followed.

EVIDENCE COVERAGE

5 of 10 members in Cancer Diagnostics are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 7 of 10 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as MYGN begins moving with the group.

Invalidation: The live read weakens if participation falls to 3 of 10 members or fewer.

Watch this read

Who this business touches

The relationships behind CAI

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ILMNIllumina, Inc.supplierMar 3, 2026

Other companies offering testing in the precision oncology industry include Illumina, NeoGenomics, Myriad Genetics, Laboratory Corporation of America, Quest Diagnostics, and BostonGene.

ABBVAbbVie Inc.partnerMay 8, 2026

Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability o…

Depended on by

BLLNBillionToOne, Inc.competitorMar 11, 2026

In the oncology market, our main competitors for our therapy selection and response monitoring tests include Caris Life Sciences, Inc., Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Guardant Health, Inc., NeoGenomics Laboratories, Inc…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 30 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CAI is currently a Follower in the organic co-movement group Cancer Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.